A series of pyrimidine hydroxamic acids with a sulfide substituent at the second position and a sulfonamide substituent at the fourth position have been synthesized and evaluated for their activity against human myeloma cell line RPMI 8226. Several compounds exhibited significant anti-cancer potency. It was found that representative compound 6a selectively killed cancerous but not normal cells. Moreover
合成了一系列
嘧啶异羟
肟酸,在第二位具有
硫化物取代基,在第四位具有磺酰胺取代基,并评估了它们对人骨髓瘤
细胞系RPMI 8226的活性。几种化合物表现出显着的抗癌效力。发现代表性化合物6a选择性杀死癌细胞,但不杀死正常细胞。此外,化合物6a可有效引起RPMI 8226细胞凋亡,并显示出有希望的H
DAC抑制活性。